EGX-A

EGX-A
Clinical data
Other namesEGXA
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of January 2024, it is in the preclinical research stage of development.

See also

References

  1. 1 2 3 "EGX A - AdisInsight". adisinsight.springer.com.
  2. 1 2 3 "Delving into the Latest Updates on EGX-A with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. 1 2 Bowen C, Khan T, Perni R, Aron R, Gibbs A, Shin R, et al. (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P362. Discovery of Novel 5-HT2A Receptor Agonists With Psychedelic Drug-Like in Vitro and in Vivo Pharmacological Activity and Therapeutic Potential for Treatment-Resistant Depression". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (275–275). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.